The FDA approved only 22 new drug candidates in 2016 — less than half of the prior year, and the lowest level since 2010. The IPO market has collapsed to its
The FDA approved only 22 new drug candidates in 2016 — less than half of the prior year, and the lowest level since 2010. The IPO market has collapsed to its lowest level since 2009. In the face of this regulatory and financial uncertainty, biotech companies must increasingly rely on creative deal-making and the discovery of new indications for established products. But that requires an entirely new approach to partnerships and pipeline strategy, from the highest levels of biotech leadership.
The FierceBiotech 2nd Drug Development Forum is unequaled at drawing together the industry\’s executive decision-makers. Its purpose is to guide you towards new strategies throughout the entire life cycle – of both your product and your company.
This year\’s agenda features:
- Over 75 expert speakers – nearly all at the VP level or C-suite
- Four detailed learning tracks covering biotech partnerships for funding, clinical research, R&D outcomes, and data resources
- Four in-depth workshops
- Learning and networking opportunities with over 350 biotech industry leaders
september 25 (Monday) - 27 (Wednesday)
Wyndham Boston Beacon Hill
5 Blossom Street, Boston, Massachusetts, 02114